Turkish Acquired Haemophilia Registry (EHEM)

Turkish Society of Hematology

Status: Unknown

Conditions: Acquired Haemophilia

Treatments: Drug: rFVIIIa, aPCC, FVIII, DDAVP, Azathioprine, Rituximab, Cyclosporin

Study type: Observational

Funder types: Other

Identifiers

NCT01403740

2011/HEM/001

Details and patient eligibility

About

Turkish Acquired Haemophilia Registry is a database in which information about clinical features and therapeutic management of acquired haemophilia is collected in Turkey.This is a multicentre, retrospective and prospective registry of subjects diagnosed and/or treated for acquired haemophilia. Patients will be registered and the response to different therapies, details of each bleeding episode and the outcome of haemostatic and immunosuppressive therapy (IST) will be recorded. Any male or female subject diagnosed with inhibitors to FVIII or other factors and treated for acquired haemophilia can be entered on the registry. Patients will be treated according to local practice. No additional tests or procedures are required by the registry. The retrospective period will not be time-limited and data will be collected from those recorded in the hospital notes. The prospective period will begin in September 1.2011, and will last for two years.

Enrollment: 250 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Acquired haemophilia diagnosis, written consent

Exclusion criteria

• Being unable to give written consent

Trial design

250 participants in 1 patient group

Acquired haemophilia patients

Treatment:

Drug: rFVIIIa, aPCC, FVIII, DDAVP, Azathioprine, Rituximab, Cyclosporin